Integra Lifesciences Affirms FY2026 EPS and Sales Guidance
Integra affirmed FY2026 adjusted EPS guidance of $2.30–$2.40 and sales guidance of $1.634 billion–$1.654 billion. The supplied estimates are $2.42 and $1.661 billion, respectively.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.